Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments Corp reported a substantial 53% year-over-year growth in Medicare Advantage membership during the annual enrollment period, reaching approximately 153,000 members, which bolsters confidence in the company's ongoing market presence. The introduction of a 4.0-Star reimbursement plan for 2026, along with anticipated improvements in new member revenue exceeding $70 PMPM, is expected to significantly enhance contribution margins. Additionally, improved medical cost ratios driven by the Clover Assistant platform are projected to yield better unit economics and margin contributions as the company expands its membership and scales in its core markets.

Bears say

Clover Health Investments Corp faces significant challenges that contribute to a negative outlook on its stock, primarily due to lower-than-expected retention of 4-Star ratings, which could impact future Medical Loss Ratios (MLR) and earnings projections. The company’s guidance suggests potential declines in gross profit margins driven by new membership dilution, while uncertainties surrounding regulatory changes and market dynamics in the Medicare Advantage landscape further complicate its financial position. Additionally, the reliance on its Clover Assistant to manage MLR trends poses risks, as any negative developments could tarnish investor confidence and provoke downward revisions in consensus forecasts.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.